Tiotropium fumarate: An interesting pharmaceutical co-crystal

Journal of Pharmaceutical Sciences

Volumn 98, Issue 5, 2009, Pages 1820-1834

  Pop, Mihaela ^a   Sieger, Peter ^b   Cains, Peter W ^a  

^a Avantium Technologies BV   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Co crystals; Crystal structure; Crystallization; Crystallography; Crystals; High throughput technologies; Materials science; Polymorphism; Spectroscopy

Indexed keywords

FUMARIC ACID DERIVATIVE; TIOTROPIUM FUMARATE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; HYDROGEN BOND; INFRARED SPECTROMETRY; RAMAN SPECTROMETRY; X RAY CRYSTALLOGRAPHY;

EID: 65949091371     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21531     Document Type: Article

References (31)

1. Vishweshwar P, McMahon J, Bis JA, Zoworotko MJ. 2006. Pharmaceutical co-crystals. J Pharm Sci 95:499-516.
2. Bučar D-K, Henry RF, Lou X, Borchardt TB, Zhang GGZ. 2007. A "hidden" co-crystal of caffeine and adipic acid. Chem Commun 5:525-527.
3. Almarrson Ö, Zaworotko MJ. 2004. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical cocrystals represent a new path to improved medicines? Chem Commun 17:1889-1896.
4. Hickey MB, Peterson ML, Scoppettuolo LA, Morrisette SL, Vetter A, Guzmán HR, Remenar JF, Zhang Z, Tawa MD, Haley S, Zaworotko MJ, Almarrson Ö. 2007. Performance comparison of a cocrystal of carbamazepine with the marketed product. Eur J Pharm Biopharm 67:112-119.
5. Remenar JF, Morrisette SL, Peterson ML, Moulton B, McPhee JM, Guzmán HR, Almarrson Ö. 2003. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 125:8456-8457.
6. Almarsson O, Bourghol Hickey M, Peterson M, Zaworotko MJ, Moulton B, Rodriguez-Hornedo N. PCT Int. Pat. Appns. 2004. WO 2004078161, WO 2004078163.
7. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic and fumaric acids. J Am Chem Soc 126:13335-13342.
8. Trask AV, Motherwell WDS, Jones W. 2005. Pharmaceutical co-crystallization: engineering a remedy for caffeine hydration. Cryst Growth Des 5:1013-1021.
9. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnel E, Park A. 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 23:1888-1897.
10. Variankaval N, Wenslow R, Murry J, Hartman R, Helmy R, Kwong E, Clas S-D, Dalton C, Santos I. 2006. Preparation and solid-state characterization of nonstoichiometric cocrystals of a phosphodiesterase- IV inhibitor and L-tartaric acid. Cryst Growth Des 6:690-700.
11. Childs SL, Stahly GP, Park A. 2007. The salt - cocrystal continuum: the influence of crystal structure on ionisation state. Mol Pharm 4:323-338.
12. Trask AV. 2007. An overview of pharmaceutical cocrystals as intellectual property. Mol Pharm 4:301-309.
13. Pop M, Mulder Houdayer S, Lamkadmi M. PCT Int. Pat. Appn. 2006. WO 2006117299.
14. Chemical Rubber Company (CRC) Handbook of Chemistry and Physics. 81st edition, CRC Press. 2000-2001. pp 9-8-9-9.
15. Max J-J, Chapados C. 2004. Infrared spectroscopy of aqueous carboxylic acids: comparison between different acids and their salts. J Phys Chem A 108:3324-3337.
16. Lecomte J. 1950. Infrared absorption spectra of metallic acetyl-acetonates. Discuss Faraday Soc 9:125-131.
17. Ertel KD, Long DF. US Pat. Appn. No. 624362, 3rd July 1997.
18. De Gelder J, De Gussem K, Vandenabeele P, Moens L. 2007. Reference database of Raman spectra of biological molecules. J Raman Spectrosc 38:1133-1147.
19. McCrone WC. 1965. Polymorphism. In: Fox D, Labes MM, Weissberger A, editors. Physics and chemistry of the organic solid state. Vol.2. New York: Wiley Interscience. pp 725-767.
20. Spek AL. 2003. Single-crystal structure validation with the program PLATON. J Appl Cryst 36:7-13.
21. Bernstein J. 2002. Polymorphism in molecular crystals. IUCr monograph on crystallography. UK: Oxford University Press.
22. Zhang ZQ, Njus JM, Sandman DJ, Guo C, Foxman BM, Erk P, van Gelder R. 2004. Diiminoisoindoline: tautomerism, conformation and polymorphism. Chem Commun 7:886-887.
23. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals. Theory and applicability of thermodynamic rules. Mikrochim Acta II:259-316.
24. Black SN, Collier EA, Davey RJ, Roberts RJ. 2007. Structure, solubility, screening and synthesis of molecular salts. J Pharm Sci 96:1053-1068.
25. Aakeröy CB, Fasulo ME, Desper J. 2007. Mol Pharm 4:317-322.
26. Prasad GS, Vijayan M. 1990. X-ray studies on crystalline complexes involving amino acids and peptides. XIX. Effects of change in chirality in the complexes of succinic acid with DL- and L-arginine. Int J Pept Protein Res 35:357-364.
27. Pop M, Goubitz K, Borodi G, Bogdan M, De Ridder DJA, Peschar R, Schenk H. 2002. Crystal structure of the inclusion complex of b-cyclodextrin with mefenamic acid from high-resolution synchrotron powder-diffraction data in combination with molecular mechanics calculations. Acta Cryst B 58: 1036-1043.
28. Pop M, Mulder Houdayer S, Sieger P, Pieper MP. US Pat. 2006. 0287530.
29. Blomsma E, van Langenvelde AJ. PCT Int. Pat. Appns. 2003. WO 2003/031959A2, WO 2003/060497A1.
30. Mackay S, Gilmore CJ, Edwards C, Stewart N, Shankland K. 1999. maXus Computer Program for the Solution and Refinement of Crystal Structures. Bruker Nonius, The Netherlands; MacScience, Japan & The University of Glasgow.
31. CCDC reference: http://www.ccdc.cam.ac.uk/products/csd-system/mercury.